Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Iodoxamic acid is a hexaiodinated, water-soluble radiographic contrast medium specifically developed for intravenous cholangiography and cholecystography. It is used to visualize the biliary tree and gallbladder during diagnostic imaging procedures, such as CT cholangiography. The drug is primarily eliminated via biliary excretion, where it achieves high concentrations in the bile to provide radiopacity. Developed by Bracco, it was marketed under brand names like Endomirabil and Endobil. While it was a standard agent for biliary imaging in the late 20th century, its use has largely been superseded by non-invasive modalities like magnetic resonance cholangiopancreatography (MRCP) and ultrasound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on iodoxamic acid.